Cargando…

Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma

In hepatocellular carcinoma (HCC), blood platelets have been linked to tumor growth, epithelial-to-mesenchymal transition (EMT), extrahepatic metastasis and a limited therapeutic response to the multikinase inhibitor (MKi) sorafenib, the standard of care in advanced HCC for the last decade. Recent c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Streubel, Gundula, Schrepfer, Sabine, Kallus, Hannah, Parnitzke, Ulrike, Wulff, Tanja, Hermann, Frank, Borgmann, Matthias, Hamm, Svetlana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100298/ https://www.ncbi.nlm.nih.gov/pubmed/33953226 http://dx.doi.org/10.1038/s41598-021-88983-1

Ejemplares similares

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
por: Ruf, Benjamin, et al.
Publicado: (2015)

Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis
por: Soukupova, Jitka, et al.
Publicado: (2017)

The therapeutic properties of resminostat for hepatocellular carcinoma
por: Zhao, Jun, et al.
Publicado: (2018)

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
por: Bretz, Anne Catherine, et al.
Publicado: (2019)

Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2021)

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells
por: Liu, Tsang-Pai, et al.
Publicado: (2017)

A randomized, double‐blind, phase II study of oral histone deacetylase inhibitor resminostat plus S‐1 versus placebo plus S‐1 in biliary tract cancers previously treated with gemcitabine plus platinum‐based chemotherapy
por: Ueno, Makoto, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
por: Demyanenko, Svetlana, et al.
Publicado: (2021)

Histone deacetylase 6 inhibition counteracts the epithelial–mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis
por: Xu, Liuqing, et al.
Publicado: (2017)

Combination of Resminostat with Ruxolitinib Exerts Antitumor Effects in the Chick Embryo Chorioallantoic Membrane Model for Cutaneous T Cell Lymphoma
por: Karagianni, Fani, et al.
Publicado: (2022)

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
por: Chang, Young, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
por: Fegerl, Gundula, et al.
Publicado: (2012)

Histone deacetylase 5 regulates the inflammatory response of macrophages
por: Poralla, Lukas, et al.
Publicado: (2015)

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
por: Li, Yan, et al.
Publicado: (2022)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Epigenetic Alterations Induced by Photothrombotic Stroke in the Rat Cerebral Cortex: Deacetylation of Histone h3, Upregulation of Histone Deacetylases and Histone Acetyltransferases
por: Demyanenko, Svetlana, et al.
Publicado: (2019)

Histone deacetylase 8 inhibition prevents the progression of peritoneal fibrosis by counteracting the epithelial-mesenchymal transition and blockade of M2 macrophage polarization
por: Zhou, Xun, et al.
Publicado: (2023)

Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes
por: Hodge, Greg, et al.
Publicado: (2015)

Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
por: Nardin, Alice, et al.
Publicado: (2016)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

Histone deacetylase 10 structure and molecular function as a polyamine deacetylase
por: Hai, Yang, et al.
Publicado: (2017)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylases in RA: epigenetics and epiphenomena
por: Grabiec, Aleksander M, et al.
Publicado: (2010)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylases and Their Inhibition in Candida Species
por: Garnaud, Cécile, et al.
Publicado: (2016)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_otlfnl9087ngse46eq7dtdqi0p